| Name | SU3327 |
| Description | SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC50 of 0.7 μM). |
| In vitro | TNF-α stimulated phosphorylation of c-Jun in HeLa cells inhibited by SU3327 with EC50 of 6.23 μM[1]. SU3327 (25 nM) pretreatment of human-derived cerebral microvascular endothelial cells (hCMEC/D3) effectively reduces LPS-induced polymorphonuclear leukocytes (PMN) rolling/adhesion to hCMEC/D3, prevents activation of AP-1, and significantly reduces expression of VCAM-1[3]. |
| In vivo | In male BKS.Cg-+Leprdb/+Leprdb/OlaHsd db/db mice, SU3327 (25 mg/kg; intraperitoneal injection; ) treatment possesses the ability to restore insulin sensitivity in mice models of diabetes[1]. SU3327 has favorable microsomal and plasma stability (T1/2 = 27 min)[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 2.5 mg/mL (9.57 mM), Sonication is recommended. DMSO : 83.3 mg/mL (318.79 mM), Sonication is recommended.
|
| Keywords | TNF-α | Thiadiazole | substrate-competitive | SU-3327 | SU3327 | SU 3327 | protein-protein | PPI | phosphorylation | p38α | JNK-JIP interactions | JNK | JIP | insulin | Inhibitor | inhibit |
| Inhibitors Related | Astragaloside IV | Teneligliptin hydrobromide | Berberine hydrogen sulphate | SP600125 | Chloranil | (-)-Bornyl acetate | Benzbromarone | Anisomycin | Chloramphenicol | Metacetamol | Berberine sulfate | Benzyl salicylate |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | PPI Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Liver Cancer Compound Library |